Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
出版年份 2021 全文链接
标题
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
作者
关键词
-
出版物
INTENSIVE CARE MEDICINE
Volume 47, Issue 6, Pages 674-686
出版商
Springer Science and Business Media LLC
发表日期
2021-05-29
DOI
10.1007/s00134-021-06431-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
- (2021) Johan A Maertens et al. LANCET
- Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?
- (2020) Bart J A Rijnders et al. CLINICAL INFECTIOUS DISEASES
- High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada
- (2020) Ilan S Schwartz et al. CLINICAL INFECTIOUS DISEASES
- Invasive Tracheobronchial Aspergillosis in Critically Ill Patients with Severe Influenza
- (2020) Remy Nyga et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pharmacokinetics and Pharmacodynamics of Posaconazole
- (2020) Lu Chen et al. DRUGS
- Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
- (2020) Paul E. Verweij et al. INTENSIVE CARE MEDICINE
- Influenza Suppresses Neutrophil Recruitment to the Lung and Exacerbates Secondary Invasive Pulmonary Aspergillosis
- (2020) Joshua M. Tobin et al. JOURNAL OF IMMUNOLOGY
- Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study
- (2020) Liang Chen et al. BMC Pulmonary Medicine
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
- (2019) J Peter Donnelly et al. CLINICAL INFECTIOUS DISEASES
- High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections
- (2019) Alexander F. A. D. Schauwvlieghe et al. MYCOSES
- Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
- (2018) Fekade B. Sime et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
- (2018) A.J. Ullmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study
- (2018) Alexander F A D Schauwvlieghe et al. Lancet Respiratory Medicine
- Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections
- (2017) Yee-Huang Ku et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Influenza A Virus as a Predisposing Factor for Cryptococcosis
- (2017) Lorena V. N. Oliveira et al. Frontiers in Cellular and Infection Microbiology
- Nationwide Surveillance of Azole Resistance in Aspergillus Diseases
- (2015) Edith Vermeulen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?
- (2015) Paul E. Verweij et al. CLINICAL INFECTIOUS DISEASES
- Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease
- (2015) Agnieszka Rynda-Apple et al. INFECTION AND IMMUNITY
- Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis
- (2014) Seyedmojtaba Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Posaconazole Plasma Concentrations in Critically Ill Patients
- (2011) John Ray et al. THERAPEUTIC DRUG MONITORING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started